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Abstract
Objective To assess the association between different types of
organisation and the results from economic evaluations.
Design Retrospective pairwise comparison of evidence
submitted to the technology appraisal programme of the
National Institute for Clinical Excellence (NICE) by
manufacturers of the relevant healthcare technologies and by
contracted university based assessment groups.
Data sources Data from the first 62 appraisals.
Main outcome measure Incremental cost effectiveness ratios.
Results Data from 27 of the 62 appraisals could be compared.
The analysis of 54 pairwise comparisons showed that
manufacturers’ estimates of incremental cost effectiveness ratios
were lower (suggesting a more cost effective use of resources)
than those produced by the assessment groups (25 were lower,
29 were the same, none were higher, P < 0.01). Restriction of
this dataset to include only one pairwise comparison per
appraisal (27 pairs) produced a similar result (21 were lower,
two were the same, four were higher, P < 0.001).
Conclusions The estimated incremental cost effectiveness
ratios submitted by manufacturers were on average significantly
lower than those submitted by the assessment groups. These
results show that an important role of NICE’s appraisal
committee, and of decision makers in general, is to determine
which economic evaluations, or parts of evaluations, should be
given more credence.
Introduction
Evidence suggests that profit making organisations are more
likely to report favourable results and conclusions from clinical
studies than non-profit organisations. The most recent of these
studies concluded that for profit organisations were 5.3 (95%
confidence interval 2.0 to 14.4) times more likely to recommend
the use of an experimental drug compared with non-profit
groups.1 Only three studies, however, have formally assessed this
association with regard to the results from economic evaluations.
One showed that evaluations of oncology products sponsored by
drug companies were less likely to report unfavourable
qualitative conclusions (5% v 38%; P = 0.04) compared with
studies sponsored by non-profit organisations.2 The two other
studies also reported similar findings.3–4
The technology appraisals programme of the National Insti-
tute for Clinical Excellence (NICE) provides guidance to the
NHS in England andWales on the use of new and existing health
technologies. Manufacturers (or relevant UK agent) of the
relevant technology, professional groups, and national groups
representing patients submit evidence. Collectively, these three
groups are known as consultees. An academic centre
commissioned through the NHS’s health technology assessment
programme, called an assessment group, also assesses the
evidence. Guidance to the NHS is formulated with regard to this
evidence, which includes information on cost effectiveness.
The criterion traditionally used to assess cost effectiveness is
the magnitude of a statistic known as the “incremental cost effec-
tiveness ratio,” defined as the difference in costs between two
technologies divided by the difference in their benefits.5 The
lower the incremental cost effectiveness ratio, the more cost
effective a technology.
We evaluated the association between source of funding and
the results from economic evaluations submitted to NICE’s tech-
nology appraisals programme.
Methods
Detailed information regarding the technology appraisals
programme is available elsewhere (www.nice.org.uk). Briefly,
after receiving the final scope of the appraisal (the scope
document outlines the patients, interventions, comparator tech-
nology, and outcomes of interest) from NICE, consultees have
about 15 weeks to submit relevant clinical and economic
evidence. During, and for a short period after, this time, the
assessment group also undertakes its independent assessment of
the clinical and economic evidence.
The appraisals committee meets twice to discuss the
evidence. After the first meeting, the committee’s preliminary
recommendations are outlined in a document called the
appraisal consultation document. At the second meeting,
consultees’ comments on this document are discussed and a final
appraisal determination is produced. If consultees do not appeal
against it, this document becomes the basis of NICE guidance.
Each manufacturer and the assessment group typically
submit an economic evaluation so that the resulting incremental
cost effectiveness ratio estimates can be compared. The institute
has published its preferred rules regarding economic methods,6
but they are not absolute.
When possible, we extracted estimated incremental cost
effectiveness ratios for the first 62 technology appraisals, issued
between March 2000 and May 2003. To do this, we needed to
address several issues. Firstly, although 62 appraisal reports had
been issued, some contained guidance on more than one aspect
of a technology. Each of these recommendations was therefore
treated as a separate observation for which cost effectiveness
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estimates could exist. Secondly, we included pairings of estimates
in the final dataset only if the manufacturer and the assessment
group had each submitted at least one incremental cost
effectiveness ratio for a technology using the same health
outcome measure—for example, a manufacturer’s estimate of the
incremental cost per quality adjusted life year (QALY) for drug A
was matched to the incremental cost per QALY for the same
drug as estimated by the assessment group. However, if the
assessment group had expressed its incremental cost effective-
ness ratio as an incremental cost per life year saved, this pairwise
comparison was excluded from the analysis. We assumed that
results from cost minimisation analyses indicated clinical equiva-
lence, together with an increase or decrease in cost and included
them in the analysis accordingly.
Over the course of an appraisal, but before the final appraisal
determination,manufacturers and assessment groups may revise
their original incremental cost effectiveness ratio estimates.
However, we restricted our analysis to estimates contained in first
submissions.
We abstracted estimates from published guidance, assess-
ment reports, and manufacturers’ submissions, and these were
double checked by a second reviewer. In the small number of
instances where the two reviewers’ estimates did not match, we
sought opinion from the relevant technology analyst at NICE.
Statistical analysis
We used two different approaches to analysis. The first
categorised incremental cost effectiveness ratio estimates
according to the scale shown in the table. Although this scale
does not reflect any rating system used by the institute at the time
these analyses were submitted, we chose the value of £30 000
(€42 792, $55 767) per unit of health outcome as one upper limit
because of published comments on NICE’s decisions.7 8 By com-
paring categories of estimates (as opposed to continuous
variables) we avoided some of the problems posed by negative
estimates.9 10
Our null hypothesis was that the incremental cost
effectiveness ratios produced by the assessment groups would
not differ systematically from those produced by manufacturers.
As the data were not continuously distributed, we performed
pairwise comparison using a two tailed Wilcoxon signed rank
test.
Our second analysis made only one comparison between the
estimates of the assessment groups and those of the manufactur-
ers involved in each technology appraisal, because more than
one pairwise comparison of incremental cost effectiveness ratio
estimates could occur (as in the first method). For example, there
might have been more than one manufacturer per appraisal or
separate results for different subgroups of patients. Such
clustered estimates will almost certainly be correlated and, if all
such estimates are used, will overestimate the accuracy of the dif-
ference being investigated. Therefore, for a given technology
appraisal, we compared the relevant pairwise comparisons
where the manufacturer’s estimate was less than the assessment
group’s estimate with the number of comparisons where the
manufacturer’s estimate was greater than the assessment group’s
estimate. Ties were excluded. We used the binomial distribution
to test the null hypothesis that, across appraisals, the assessment
group estimates would be lower than those of manufacturers as
often as they would be higher. Unlike the first method, this
analysis was based on point estimates rather than categories of
cost effectiveness.
Results
Of the 62 appraisals, we excluded 35 because the assessment
group alone did not produce an incremental cost effectiveness
ratio (n = 20), there was no manufacturer or the manufacturer
did not produce an estimate (n = 3), the assessment group and
the manufacturer did not produce an estimate (n = 8), or differ-
ent measures of health benefit were used (n = 4). The 27 remain-
ing appraisals contained 54 pairwise comparisons.
Over 80% of the manufacturers’ incremental cost effective-
ness ratios were between dominant (meaning that the appraised
technology was considered to be less costly and more effective
than the comparator technology) and £15 000 per unit of
outcome (categories 0 and 1 combined) whereas the assessment
groups’ estimates were more uniformly distributed over the five
categories (fig 1). Only four (7%) estimates from manufacturers
were above £30 000 per unit of outcome compared with 19
(35%) estimates from the assessment groups.
There were 25 cases of negative rank (where the manufactur-
ers’ estimates were lower than those of the corresponding assess-
ment group), 29 ties (where the estimates were in the same
category), and no positive ranks (P < 0.01; see box for example).
Sensitivity analysis around the category definitions did not alter
the significance of this result. Figure 2 plots the log of these pair-
wise comparisons; the 45° line indicates identical incremental
cost effectiveness ratios. Points above this line indicate that a
manufacturer’s estimate was higher (less favourable) than the
estimate produced by the assessment group, whereas points
below this line indicate the manufacturer submitted a lower
(more favourable) estimate than that of the assessment group.
The analysis conducted with the second method reduced the 54
pairs of incremental cost effectiveness ratios to 27 pairs, of which
two were a tie. The analysis showed that in 21 instances the
manufacturers’ estimates were lower than the assessment groups’
estimates and in the four remaining they were higher (P < 0.001).
Categories of cost effectiveness
Category
Incremental cost effectiveness estimate per unit of
health outcome
0 Negative incremental cost effectiveness ratios favouring
use of technology or, in case of cost minimisation
analysis, cheaper than alternative technology
1 From £1 to £15 000
2 From £15 001 to £30 000
3 More than £30 000
4 Negative incremental cost effectiveness ratios not
favouring use of technology or, in case of cost
minimisation analysis, more expensive than alternative
technology
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Fig 1 Distribution of estimates of incremental cost effectiveness ratios from
assessment groups and manufacturers according to category of cost
effectiveness (see table)
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Discussion
We assessed whether results from economic evaluations by con-
tracted academic centres (assessment groups) and by manufac-
turers of technologies were similar. Our analysis showed that the
estimates of incremental cost effectiveness ratio submitted by
manufacturers were on average significantly lower than those
provided by the assessment groups. This finding is similar to
those reported by others.2–4 Unlike previous studies, however,
ours is based on specific pairwise comparisons of estimates that
have been put forward for the same purposes and constructed
with the same terms of reference (the scope document).
Whether differences between competing cost effectiveness
estimates ultimately matter in terms of decision making depends
on several factors, including the level of uncertainty surrounding
the incremental cost effectiveness ratios11 and their absolute
value. One method of assessing this would have been to divide
the dataset into two, with one section including all pairings that
contained at least one estimate above an implied maximum
threshold of willingness to pay and another containing the
remaining pairs of observations. However, the dataset was
considered to be too small to do this. Nevertheless, when differ-
ences in estimated incremental cost effectiveness ratios do lead
to different conclusions, the role of the appraisal committee is to
judge the appropriateness of each evaluation and to determine
which estimate is the most reasonable.12
NICE will soon be adopting a “reference case” approach
designed to be the most appropriate for the NHS to improve
consistency across all submitted economic evaluations.13 It is
therefore feasible that differences between estimated incremen-
tal cost effectiveness ratios submitted will be smaller in the future.
We used two different analyses because, though the first
method was more informative, we were concerned about the
possibility of overstating the accuracy of the difference being
investigated. Both approaches, however, produced similar results
and led to the same conclusion.
Limitations of study
A limitation of this study is that the evaluations submitted by a
manufacturer and the corresponding assessment group are not
totally independent, as the assessment group has usually had the
opportunity to review the manufacturer’s evaluation before
completing its own. In contrast, manufacturers do not have the
opportunity to review the assessment group’s evaluation until it
has been submitted to the institute. It is difficult to gauge,
however, whether this is likely to lead to systematic differences in
the paired ratios or influence the extent or direction of this
difference.
It is also feasible that differences in estimates are not uniform
across all categories of cost effectiveness. Logic would suggest
that because technologies with high incremental cost effective-
ness ratios are less likely to be recommended for use within the
NHS, groups with vested interests in a technology might under-
estimate incremental cost effectiveness when the “true” estimate
is high than when it is low. Insufficient data existed to test this
hypothesis.
The reasons that incremental cost effectiveness ratios varied
within each appraisal have not yet been investigated. For the
moment, we can conclude only that estimates from manufactur-
ers and assessment groups were significantly different from each
other, not that biased results were associated with either type of
organisation.
Conclusions
In conclusion, we have shown that incremental cost effectiveness
ratios submitted to NICE’s technology appraisals programme by
different types of organisation were significantly different from
each other. These findings undoubtedly pose questions as to the
appropriate methods and processes used by the institute (and
reimbursement agencies in general) when determining cost
effectiveness. They also highlight the need for decision makers to
have unhindered access to the methods used to produce cost
effectiveness estimates so that they can be examined in detail.
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Fig 2 Logged pairwise comparison of incremental cost effectiveness ratios. Only
45/54 pairs of recommendations have been plotted because remaining nine pairs
contained at least one negative estimate and could not be logged. However, in six
of nine pairs estimates from the two sources were broadly similar and in three
pairs estimates reported by manufacturers were much more favourable towards
the technology than those reported by the assessment groups
Example of a pairwise comparison—appraisal No 22
Guidance on the use of orlistat for the treatment of obesity in
adults
The manufacturer estimated the incremental cost effectiveness
ratio to be about £10 500 per QALY, whereas the assessment
group estimated a baseline estimate of about £46 000 per QALY.
Therefore, for the first method we coded the manufacturer’s
estimate as category 1 and the assessment group’s estimate as
category 3, indicating a negative rank. For the second method,
the single manufacturer ratio was less than that of the assessment
group.
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What is already known on this topic
Economic evaluations are used to produce estimates of the
cost effectiveness of healthcare technologies
Profit making organisations are more likely to report
favourable outcomes from clinical and economic studies
than non-profit organisations
One of the key roles of NICE’s appraisal committee is to
judge the appropriateness of each evaluation and to
determine which estimate is the most reasonable
What this study adds
Economic evaluations submitted by manufacturers to
NICE’s technology appraisals programme were significantly
more favourable than evaluations produced by academic
research groups
The findings pose questions as to the appropriate methods
and processes used by NICE (and reimbursement agencies
in general) in the determination of cost effectiveness
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